NEW YORK (GenomeWeb) – GenomeDx Biosciences today announced that national Medicare benefit administration contractor Palmetto GBA has issued a positive coverage policy for the firm's Decipher prostate cancer classifier.

Palmetto issued the policy through the MolDx program, which it runs for the Centers for Medicare and Medicaid Services. In October 2014, Palmetto issued a preliminary local coverage determination for Decipher on behalf of CMS.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.